CFFT Funds Safety Testing of Anti-Microbial Drug to Fight Drug-Resistant Bacteria

Cystic Fibrosis Foundation Therapeutics Inc. will award up to $1.7 million to Alaxia SAS to test the safety of a potential inhaled therapy that may fight drug-resistant bacteria that infect people with cystic fibrosis

| 2 min read

Cystic Fibrosis Foundation Therapeutics Inc. (CFFT) will provide up to $1.7 million to Alaxia SAS to expedite development and test the safety of a potential inhaled therapy that may fight drug-resistant bacteria that pose a serious health risk to people with cystic fibrosis. CFFT is the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation.

The drug ALX-009 is a combination of two substances that are naturally found in healthy lungs and help the immune system fight infections. These two antimicrobial molecules -- the hypothiocyanite anion and the protein lactoferrin -- are not present or are deficient in lungs with cystic fibrosis. 

Laboratory tests have shown that ALX-009 has been effective in killing bacteria in lung mucus and biofilms, interwoven layers of bacteria and other material that make bacteria resistant to drugs, according to Annie-Claude Benichou, M.D., chief medical officer of Alaxia. 

Alaxia tested the drug against a wide range of bacterial species that infect people with CF, particularly drug-resistant bacteria such as Burkholderia cepacia complex (B. cepacia)Achromobacter xylosoxidans and some strains of Pseudomonas aeruginosa.

Phase 1 clinical trial to test for safety is underway in France, where Alaxia is based. The trial should be complete by next spring, according to Dr. Benichou.

Share this article
Topics
Research
Recent news
Teens Advocate for the PASTEUR Act as Part of the CF Foundation’s 14th Annual Teen Advocacy Day
News | 4 min read
CF Foundation Awards $1.6 Million to Improve Detection of Lung Transplant Complication
News | 5 min read
CF Foundation Announces New National Advocacy Chairs
News | 5 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe